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Background: PGE2, synthesized by cyclooxygenase-2 (COX-2), is re-
lated with cellular immune tolerance in cancer development. Although 
the potential of immune tolerance associated with tumor-produced 
COX-2 has been suggested, the mechanism of immune tolerance is not 
yet well deﬁned. Induction of tolerance required a speciﬁc environment 
in which plasmacytoid dendritic cells (pDCs) and regulatory T cells 
(Treg) play an essential role. It was recently shown that maturation 
of DCs in the presence of indoleamine 2,3-dioxygenase (IDO) results 
in activation of Treg, and inhibition of COX-2 activity regulates IDO 
expression within the tumor microenvironment. IDO is an emerging 
immuno-regulatory enzyme that can block T lymphocyte activation and 
induce Treg. Thus, we hypothesized that the anti-tumor immunity of 
COX-2 inhibitor could be partly due to IDO-dependent Treg activa-
tion. To test this hypothesis, we evaluated Treg and IDO expression in 
mouse tumor model treated with COX-2 inhibitor.
Methods: The Lewis lung cancer cells (3LL) originated from C57Bl/6 
mouse were inoculated in each mouse. Total 20 mice were randomized 
into normal control, 3LL inoculated control, and low and high dose 
COX-2 inhibitor (celecoxib was given once a day for 3 weeks by oral 
gavage, 10 or 100mg/kg/day) treated groups (N=5 per group). Mice 
were sacriﬁced on day 28. The tumor mass and spleen were removed 
for immunoblotting and ﬂow cytometry analysis. The pDCs were iso-
lated from splenocytes by magnetic cell sorting. The number of surface 
lung tumor and tumor mass size were compared between groups.
Results: The pDCs cultured in COX-2 inhibitor supernatants showed a 
signiﬁcant decrement in IL-10 production (p<0.05). The COX-2, IDO 
and Foxp3 expression were decreased in the tumor mass of COX-2 
inhibitor treated mice, and this was found to correlate with reduced 
tumor mass and metastasis. Treg cells were decreased in COX-2 inhibi-
tor treated groups (p<0.05) and positive correlation exists between Treg 
cell and tumor volume. 
Conclusion: The COX-2 inhibition decrease immune tolerogenic 
IL-10 production in pDCs. The expression of IDO and Treg cells are 
decreased in COX-2 inhibited 3LL tumor bearing mice groups. The 
present study shows that COX-2 inhibitors promote antitumor reactiv-
ity by inhibiting IDO and Treg activity.
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Background: DNA damage response (DDR) pathways play important 
roles in the maintenance of genomic stability, and their inactivation is 
critically involved in multi-step carcinogenesis. We have shown the 
presence of frequent impairment of DNA damage checkpoints as well 
as of mitotic checkpoints in lung cancer, suggesting their involvement 
in lung carcinogenesis. A hypomorphic 657del5 mutation of NBS1, a 
key DDR component, is responsible for the rare cancer-predisposing, 
Nijmegen breakage syndrome (NBS), which has been reported almost 
exclusively in the Slavic population thus far. 
Methods: We evaluated the S phase checkpoint status by examining 
radioresistant DNA synthesis (RDS) in 14 lung cancer cell lines and 
normal human ﬁbroblasts. NBS1 alteration was sought for in a small 
cell lung cancer (SCLC) cell line with impaired S-phase checkpoint 
in RDS assay, and was characterized by sequencing and biochemi-
cal analyses. The identiﬁed NBS1 mutation was screened for in the 
germline of 1,743 patients with various types of cancers as well as of 
2,348 control subjects. Association between NBS1 mutation and cancer 
incidence was examined using two-sided Fisher’s exact test. 
Results: We identiﬁed for the ﬁrst time in the Japanese popula-
tion an unprecedented type of heterozygous NBS1 mutant, termed 
IVS11+2insT, lacking the MRE11- and ATM-binding sites at the C ter-
minus. It was found to be profoundly defective in terms of the crucial 
binding to MRE11, ATM, wt-NBS1, BRCA1, and unexpectedly also 
to MDC1, while the mutant also demonstrated impaired ATM phos-
phorylation in response to low dose irradiation (IR) in the heterozygous 
state. In our initial screening, the IVS11+2insT mutation was in fact 
identiﬁed in 1 tumor among 200 primary lung cancer cases. Important-
ly, while IVS11+2insT was found in only 2 (0.09%) of 2,348 control 
subjects, it was identiﬁed in 2% (2 of 96) of heterozygotes with gastric 
cancer, 0.8% (3 of 376) of those with colorectal cancer, and 0.4% (2 of 
532) of those with lung cancer, which were comparable to frequencies 
reported for other DDR-related genes conferring cancer susceptibility, 
with odds ratios of 25.0 (95% conﬁdence interval (CI) [1.78-346.0]) for 
gastric and 9.43 (95%CI [1.08-113.3]) for colorectal cancer. 
Conclusion: This novel NBS1 mutation, IVS11+2insT, may be cru-
cially involved in the predisposition to common types of cancers in the 
Japanese patients. Thus, additional investigation is warranted, includ-
ing more detailed phenotypic characterization, such as frequency and 
penetrance in cases with familial aggregation as well as screening in 
other ethnic groups.
